Life of Research
Appearance
Preprint Open access CC BY 4.0

Schizophrenia: Understanding Its Pathophysiology, Therapeutic Approaches, and Advances in Pharmacological Management

  • Dhiraj Sanjay Patil
  1. P.S.G.V.P. Mandal's College of Pharmacy, Shahada, Maharashtra, India.

Preprint

LOR-00235

Download PDF (299 KB) Cite

Cite

Schizophrenia: Understanding Its Pathophysiology, Therapeutic Approaches, and Advances in Pharmacological Management

Read

Abstract

Schizophrenia is a complex and often long-term mental health condition that can affect perception, thinking, emotional expression, motivation and everyday functioning. It is not explained by a single cause or one isolated brain abnormality. Current understanding points towards an interaction among genetic susceptibility, early neurodevelopment, environmental exposures and changes in the communication systems that connect different brain regions. Symptoms are commonly discussed in three broad domains: positive symptoms, such as hallucinations and delusions; negative symptoms, such as reduced motivation and social withdrawal; and cognitive difficulties involving attention, memory and executive functioning.

Antipsychotic medicines remain central to the management of acute psychotic symptoms and relapse prevention. However, medication alone is rarely sufficient to address every aspect of the condition. Psychological interventions, family education, social-skills development, rehabilitation, supported education or employment, and attention to physical health contribute to a more complete model of care. Treatment must be individualised because antipsychotic medicines differ in their effectiveness and adverse-effect profiles. Important safety concerns include metabolic changes, movement disorders, sedation, raised prolactin, cardiovascular effects and, rarely, neuroleptic malignant syndrome.

This narrative review brings together the key themes of the supplied academic report: aetiology, neurobiology, clinical presentation, diagnosis, pharmacological and psychosocial treatment, medicine-related risks, and the role of pharmacists. It also places these themes in the context of contemporary guidance, with emphasis on shared decision-making, early assessment, systematic monitoring and recovery-oriented care. The central message is that schizophrenia is treatable and that sustained, respectful, person-centred support can improve symptoms, functioning and quality of life.

Keywords

Files (1)

Cite this record

Patil, D. S. (2026). Schizophrenia: Understanding Its Pathophysiology, Therapeutic Approaches, and Advances in Pharmacological Management [Preprint]. Life of Research. https://lifeofresearch.com/preprints/235

APA 7th edition
Export to a reference manager
BibTeX
@misc{patil2026schizophrenia,
  author       = {Patil, Dhiraj Sanjay},
  title        = {{Schizophrenia: Understanding Its Pathophysiology, Therapeutic Approaches, and Advances in Pharmacological Management}},
  year         = {2026},
  month        = nov,
  date         = {2026-11-17},
  publisher    = {Life of Research},
  howpublished = {Preprint},
  url          = {https://lifeofresearch.com/preprints/235},
  abstract     = {Schizophrenia is a complex and often long-term mental health condition that can affect perception, thinking, emotional expression, motivation and everyday functioning. It is not explained by a single cause or one isolated brain abnormality. Current understanding points towards an interaction among genetic susceptibility, early neurodevelopment, environmental exposures and changes in the communication systems that connect different brain regions. Symptoms are commonly discussed in three broad domains: positive symptoms, such as hallucinations and delusions; negative symptoms, such as reduced motivation and social withdrawal; and cognitive difficulties involving attention, memory and executive functioning.

Antipsychotic medicines remain central to the management of acute psychotic symptoms and relapse prevention. However, medication alone is rarely sufficient to address every aspect of the condition. Psychological interventions, family education, social-skills development, rehabilitation, supported education or employment, and attention to physical health contribute to a more complete model of care. Treatment must be individualised because antipsychotic medicines differ in their effectiveness and adverse-effect profiles. Important safety concerns include metabolic changes, movement disorders, sedation, raised prolactin, cardiovascular effects and, rarely, neuroleptic malignant syndrome.

This narrative review brings together the key themes of the supplied academic report: aetiology, neurobiology, clinical presentation, diagnosis, pharmacological and psychosocial treatment, medicine-related risks, and the role of pharmacists. It also places these themes in the context of contemporary guidance, with emphasis on shared decision-making, early assessment, systematic monitoring and recovery-oriented care. The central message is that schizophrenia is treatable and that sustained, respectful, person-centred support can improve symptoms, functioning and quality of life.},
  keywords     = {Schizophrenia; Psychosis; Pathophysiology; Dopamine; Antipsychotic medicines; Psychosocial intervention; Adverse drug reactions; Medication adherence; Pharmacist; Recovery},
  language     = {en},
  copyright    = {Creative Commons Attribution 4.0}
}

Using Zotero or Mendeley? Their browser connector saves this record from this page, with its PDF when there is one. On search and browse pages it lists every result so you can save many at once.

Guides How to cite a preprint Preprints vs journal articles What CC BY 4.0 allows

References (13)

  1. World Health Organization. Schizophrenia. Fact sheet. 11 September 2026. Available at: https://www.who.int/en/news-room/fact-sheets/detail/schizophrenia
  2. American Psychiatric Association. DSM-5: Changes in the diagnosis of schizophrenia. Available at: https://www.psychiatry.org/File%20Library/Psychiatrists/Practice/DSM/APA_DSM-5-Schizophrenia.pdf
  3. National Institute for Health and Care Excellence (NICE). Psychosis and schizophrenia in adults: prevention and management. Clinical guideline CG178. Updated 4 September 2026. Available at: https://www.nice.org.uk/guidance/cg178
  4. Japanese Society of Neuropsychopharmacology and Japanese Society of Clinical Neuropsychopharmacology. Guideline for pharmacological treatment of schizophrenia 2022. Neuropsychopharmacology Reports. 2025;45:e12497. https://pmc.ncbi.nlm.nih.gov/articles/PMC11666347/
  5. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020;19:15–33. https://doi.org/10.1002/wps.20693.
  6. Harrison PJ, Weinberger DR. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Molecular Psychiatry. 2005;10:40–68. https://doi.org/10.1038/sj.mp.4001558.
  7. Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Archives of General Psychiatry. 2003;60:1187–1192.
  8. Keepers GA, Fochtmann LJ, Anzia JM, et al. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia. American Journal of Psychiatry. 2020;177:868–872.
  9. Barnes TRE, et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology. 2020;34:3–78.
  10. Galletly C, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the management of schizophrenia and related disorders. Australian & New Zealand Journal of Psychiatry. 2016;50:410–472.
  11. Kahn RS. On the origins of schizophrenia. American Journal of Psychiatry. 2020;177:291–297.
  12. Dennison CA, Legge SE, Pardiñas AF, Walters JTR. Genome-wide association studies in schizophrenia: recent advances, challenges and future perspective. Schizophrenia Research. 2020;217:4–12.
  13. Martini LC, Barbosa Neto JB, Petreche B, et al. Schizophrenia and work: aspects related to job acquisition in a follow-up study. Revista Brasileira de Psiquiatria. 2018;40:35–40.